MX2017013073A - Inhibidores de grelina o-aciltransferasa. - Google Patents

Inhibidores de grelina o-aciltransferasa.

Info

Publication number
MX2017013073A
MX2017013073A MX2017013073A MX2017013073A MX2017013073A MX 2017013073 A MX2017013073 A MX 2017013073A MX 2017013073 A MX2017013073 A MX 2017013073A MX 2017013073 A MX2017013073 A MX 2017013073A MX 2017013073 A MX2017013073 A MX 2017013073A
Authority
MX
Mexico
Prior art keywords
ghrelin
transferase inhibitors
acyl transferase
inhibitors
acyl
Prior art date
Application number
MX2017013073A
Other languages
English (en)
Inventor
James Hembre Erik
Stanley Galka Christopher
Allan Honigschmidt Nicholas
Angeles Martinez Grau Maria
Ruano Plaza Gema
Rubio Almudena
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017013073A publication Critical patent/MX2017013073A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona nuevos inhibidores de GOAT y sus sales y composiciones farmacéuticas.
MX2017013073A 2015-04-15 2016-04-13 Inhibidores de grelina o-aciltransferasa. MX2017013073A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382180 2015-04-15
PCT/US2016/027177 WO2016168222A1 (en) 2015-04-15 2016-04-13 Ghrelin o-acyl transferase inhibitors

Publications (1)

Publication Number Publication Date
MX2017013073A true MX2017013073A (es) 2017-12-04

Family

ID=52991669

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013073A MX2017013073A (es) 2015-04-15 2016-04-13 Inhibidores de grelina o-aciltransferasa.

Country Status (16)

Country Link
US (1) US10093651B2 (es)
EP (1) EP3283473B1 (es)
JP (1) JP6458168B2 (es)
KR (1) KR20170123693A (es)
CN (1) CN107428723B (es)
AR (1) AR104672A1 (es)
AU (1) AU2016247901A1 (es)
BR (1) BR112017017835A2 (es)
CA (1) CA2976636A1 (es)
EA (1) EA201791992A1 (es)
ES (1) ES2715763T3 (es)
IL (1) IL253969A0 (es)
MX (1) MX2017013073A (es)
TW (1) TWI589574B (es)
WO (1) WO2016168222A1 (es)
ZA (1) ZA201705675B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017307033B2 (en) 2016-08-05 2020-11-26 Boehringer Ingelheim International Gmbh Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
JP7225253B2 (ja) 2018-02-02 2023-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo-アシルトランスフェラーゼ(goat)阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体
CA3087925A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2020008053A (es) * 2018-02-02 2020-09-07 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat).
CN111655699B (zh) 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的杂环基取代的噁二唑并吡啶衍生物
CN108610337A (zh) * 2018-05-30 2018-10-02 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
WO2021233884A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
EP4153599B1 (en) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060233788A1 (en) 2003-09-05 2006-10-19 Heiman Mark L Anti-ghrelin antibodies
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
US20070237775A1 (en) 2004-07-14 2007-10-11 Eli Lilly And Company Anti-Ghrelin Antibodies
CA2587627A1 (en) 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
US7479271B2 (en) 2005-02-23 2009-01-20 Eli Lilly And Company Humanized anti-ghrelin antibodies
JP6106179B2 (ja) * 2012-02-24 2017-03-29 武田薬品工業株式会社 芳香環化合物
UA118034C2 (uk) * 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази

Also Published As

Publication number Publication date
CN107428723A (zh) 2017-12-01
WO2016168222A1 (en) 2016-10-20
TW201704225A (zh) 2017-02-01
AR104672A1 (es) 2017-08-09
JP2018511630A (ja) 2018-04-26
ZA201705675B (en) 2019-07-31
CA2976636A1 (en) 2016-10-20
ES2715763T3 (es) 2019-06-06
US20180086732A1 (en) 2018-03-29
CN107428723B (zh) 2020-05-05
EP3283473B1 (en) 2019-01-02
EP3283473A1 (en) 2018-02-21
KR20170123693A (ko) 2017-11-08
BR112017017835A2 (pt) 2018-04-10
AU2016247901A1 (en) 2017-09-14
TWI589574B (zh) 2017-07-01
US10093651B2 (en) 2018-10-09
IL253969A0 (en) 2017-10-31
JP6458168B2 (ja) 2019-01-23
EA201791992A1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
PH12016500895A1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
MX2017013072A (es) Inhibidores de grelina o-aciltransferasa.
GEP20217239B (en) Pharmaceutical composition
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
TW201613892A (en) Forms and compositions of an ERK inhibitor
BR112017017835A2 (pt) inibidores de grelina o-acil transferase
GEP20217240B (en) Pharmaceutical composition
PL3494120T3 (pl) Pochodne oksadiazolopirydyny do zastosowania jako inhibitory o-acylotransferazy greliny (goat)
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
PH12017502028A1 (en) Vortioxetine pyroglutamate
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
AU360128S (en) Adjustable label tie